36 results about "Prostaglandin F2alpha" patented technology

The present invention provides a new and effective process for the synthesis of 17-phenyl-18,19,20-trinor-PGF2 alpha and its derivatives, including the anti-glaucoma drugs Bimatoprost and Latanoprost. The benefit of the present invention rises inter alia from the fact that a major intermediate involved in the synthesis of the above compounds may be isolated from a mixture containing also an undesired isomer, by crystallization. In addition, the undesired isomer may be oxidized to give the starting compound, which is then recycled.

The invention relates to compositions which are useful for inhibiting prostaglandin F2αreceptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.

The present invention provides a resin-made container which enables long-term stable preservation of aqueous liquid preparations containing prostaglandin F2a derivatives having fluorine atoms in the molecule. An aqueous liquid preparation containing a prostaglandin F2a derivative having a fluorine atom in the molecule is protected from lowering in the prostaglandin F2a derivative content by keeping the preparation in a container made of a propylene / ethylene copolymer having a propylene / ethylene ratio of 94.0 / 6.0 to 99.5 / 0.5.

Provided are methods for determining the level of microglial activation in the brain of a subject by measuring blood Prostaglandin E2 (PGE2), Prostaglandin F2α, or both, and C-Reactive Protein (CRP) concentrations in a sample obtained from a subject, wherein the ratio of [PGE2] / [CRP], [PGF2α] / [CRP], or both, is indicative of the level of microglial activation in the brain of the subject.

An object of the present invention is to provide a stable aqueous pharmaceutical composition which suppresses degradation of prostaglandin F 2 alpha in a preparation containing prostaglandin F 2alpha. The object was attained by formulating a prostaglandin F 2alpha derivative into an oil-in-water emulsion together with an oil, for example, medium chain fatty acid triglyceride, a water-soluble polymer and water.

The invention relates to conformation-constrained entirely-synthetic macrocyclic compounds. A conformation-constrained, space-defined 12-30-member macrocyclic system (I) which is as shown in the description comprises three different constitution units: an aromatic template a, a confor1ation regulator b and a spaced part c, which are illustrated in the description and the claims. The macrocyclic compounds (I) can be easily prepared according to a parallel synthesis method or a combinatorial chemistry method, and are designed for realizing interaction with a specific biological target. Particularly, the compounds show agonistic or antagonistic activity to the following matters: a motilin receptor (MR), a 5-hydroxytryptamine receptor (5-HT2B receptor) of a subtype 5-HT2B, and a prostaglandin F2alpha receptor (FP receptor). Thus, the compounds are effectively used for treating gastrointestinal tract hypomotility disorder such as diabetic gastroparesis and constipation-predominant irritable bowel syndrome, CNS-related diseases such as migraine, schizophrenia, psychosis and depression, ocular hypertension such as glaucoma-related ocular hypertension, and premature delivery.

A method of protecting a retinal neuronal cell by administering an effective amount of a prostaglandin F2α derivative to a patient. A method of preventing or treating an eye disease associated with retinal neuronal cell damage by administering a therapeutically effective amount of a prostaglandin F2α derivative to a patient.